Deakin University
Browse

Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial

Download (366.04 kB)
Version 2 2024-06-06, 11:44
Version 1 2015-03-24, 14:34
journal contribution
posted on 2024-06-06, 11:44 authored by G Flaker, RD Lopes, E Hylek, DM Wojdyla, L Thomas, SM Al-Khatib, RM Sullivan, SH Hohnloser, D Garcia, M Hanna, J Amerena, VP Harjola, P Dorian, A Avezum, M Keltai, L Wallentin, CB Granger
Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin.

History

Journal

Journal of the American college of cardiology

Volume

64

Pagination

1541-1550

Location

San Diego, CA

Publisher DOI

Open access

  • Yes

Link to full text

ISSN

0735-1097

eISSN

1558-3597

Language

eng

Author URL

Publication classification

C Journal article, C1 Refereed article in a scholarly journal

Copyright notice

2014, Elsevier

Issue

15

Publisher

Elsevier

Usage metrics

    Research Publications

    Categories

    Keywords

    antiarrhythmia agentsanticoagulantsantithrombotic agentsfactor XastrokethromboembolismwarfarinAgedAmiodaroneAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationBrazilCause of DeathDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyEuropeFactor Xa InhibitorsFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedOntarioPyrazolesPyridonesStrokeSurvival RateThromboembolismTreatment OutcomeUnited StatesWarfarinSchool of Medicine119999 Medical and Health Sciences not elsewhere classified929999 Health not elsewhere classified

    Licence

    All Rights Reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC